# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-048239
Filing Date
2024-12-03
Accepted
2024-12-03 08:03:46
Documents
8
Period of Report
2025-01-23

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20035571x1_def14a.htm | DEF 14A | 817720
2 |  | logo_galectin.jpg | GRAPHIC | 26119
3 |  | ny20035571x1_pvpchart1.jpg | GRAPHIC | 140847
4 |  | ny20035571x1_pvpchart2.jpg | GRAPHIC | 120414
5 |  | sig_jlewis.jpg | GRAPHIC | 12813
6 |  | sig_jwcallicutt.jpg | GRAPHIC | 17818
7 |  | ny20035571x1_pc01.jpg | GRAPHIC | 554419
8 |  | ny20035571x1_pc02.jpg | GRAPHIC | 526357
| Complete submission text file | 0001140361-24-048239.txt |  | 2743802

Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-31791 | Film No.: 241521213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)